No abstract

Background. In the ght against coronavirus infection, an important direction is control of herd immunity to the pathogen. SARS-CoV-2 herd immunity is formed naturally as a result of manifest or asymptomatic infection, or arti cially as a result of vaccination Aim: To assess the SARS-CoV-2 herd immunity status of the Kyrgyz population. Materials and methods. A cross-sectional, randomized study of SARS-CoV-2 herd immunity was carried out according to a program developed by Rospotrebnadzor, with the participation of the Saint Petersburg Pasteur Institute, taking into account WHO recommendations. In all study stages cloud service (internet) technologies were used. The ethics committees of the Preventive Medicine Association (Kyrgyzstan) and the Saint Petersburg Pasteur Institute (Russia) approved the study. A total of 9,471 volunteers were selected, representing 0.15% (95% CI 0.14-0.15) of the total population. They were randomized according to age and region. Antibodies (Abs) to the nucleocapsid antigen (Nag) were determined by enzyme-linked immunosorbent assay (ELISA) of volunteer blood plasma. For vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Statistical processing of the results was carried out using Excel 2010 and other programs. Differences were designated as statistically signi cant at p<0.05.Results. The seroprevalence of the general population was 48.7% (95% CI 47.7-49.7), with a maximum in the group of '60-69 year old' (59.2% (56.6-61.7)) and a minimum in the group '1-17 y.o.' (32.7% (95 CI 29.4-36.1)). The largest proportion seropositive was found in the Chui region (51.3% (95% CI 47.9-54.8)).The lowest was in Osh city )). The maximum seropositivity was detected among healthcare workers (57.1% (95% CI 55.4-58.8); the minimum was noted among artists (38.6% (95% CI 26.0-52.4)). Asymptomatic SARS-CoV-2 positivity was 79.1% (96% CI 77.9-80.3). Vaccination with Sputnik V, EpiVacCorona, or Sinopharm formed comparable levels of immunity.Conclusions. The herd immunity to SARS-CoV-2 Nag is 48.75% (95% CI 47.7-49.7), and the overall immunity (Nag + RBDag) is 57%.

Background. In the fight against coronavirus infection, an important direction is control of herd immunity to the pathogen. SARS-CoV-2 herd immunity is formed naturally as a result of manifest or asymptomatic infection, or artificially as a result of vaccination Aim: To assess the SARS-CoV-2 herd immunity status of the Kyrgyz population. Materials and methods. A cross-sectional, randomized study of SARS-CoV-2 herd immunity was carried out according to a program developed by Rospotrebnadzor, with the participation of the Saint Petersburg Pasteur Institute, taking into account WHO recommendations. In all study stages cloud service (internet) technologies were used. The ethics committees of the Preventive Medicine Association (Kyrgyzstan) and the Saint Petersburg Pasteur Institute (Russia) approved the study. A total of 9,471 volunteers were selected, representing 0.15% (95% CI 0.14-0.15) of the total population. They were randomized according to age and region. Antibodies (Abs) to the nucleocapsid antigen (Nag) were determined by enzyme-linked immunosorbent assay (ELISA) of volunteer blood plasma. For vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Statistical processing of the results was carried out using Excel 2010 and other programs. Differences were designated as statistically significant at p<0.05. Results. The seroprevalence of the general population was 48.7% (95% CI 47.7-49.7), with a maximum in the group of '60-69 year old' (59.2% (56.6-61.7)) and a minimum in the group '1-17 y.o.' (32.7% (95 CI 29.4-36.1)). The largest proportion seropositive was found in the Chui region (51.3% (95% CI 47.9-54.8)). The lowest was in Osh city (38.1% (95 CI 32.6-43.9)). The maximum seropositivity was detected among healthcare workers (57.1% (95% CI 55.4-58.8); the minimum was noted among artists (38.6% (95% CI 26.0-52.4)). Asymptomatic SARS-CoV-2 positivity was 79.1% (96% CI 77.9-80.3). Vaccination with Sputnik V, EpiVacCorona, or Sinopharm formed comparable levels of immunity. Conclusions. The herd immunity to SARS-CoV-2 Nag is 48.75% (95% CI 47.7-49.7), and the overall immunity (Nag + RBDag) is 57%.

Children in Central Asia and the Middle East bear disproportionate environmental threats to health, of which the most widespread and serious result from poverty, malnutrition, lack of access to safe drinking water and food, and exposures to toxic chemicals. Their psychological health is threatened in several parts of this region by internal wars and strife. Many, or even most, children are regularly exposed to environmental tobacco smoke. In many of these countries, children constitute very high percentages of the population. Because children constitute the future, it is critical that these threats to their health be addressed and reduced to the greatest extent possible through both provision of safe and adequate drinking water and nutrition and reduction of exposures to environmental contaminants.

Aim. The development of the hepatitis E virus (HEV) genotype 1 recombinant capsid protein. Materials and methods. Escherichia coli strains, plasmid vectors, serological and clinical samples, ELISA reagent kits, molecular biological, bioinformatic, biotechnological, biochemical and serological methods. Results. Using HEV genotype 1 DNA copy of subgenomic virus RNA we made E.coli strains producing recombinabt capsid protein, containing C-terminal fragment of ORF2 protein fused to E.coli beta-galactosidase. Recombinant protein ORF2 had been isolated from the inclusion bodies of the E.coli biomass and purified by size exclusion chromatography. By Western blotting it had been shown specific interaction of the recombinant polypeptide with anti-HEV IgG from pool of positive sera. Antigenic specificity of the recombinant polypeptide had been confirmed by enzyme-linked immunosorbent assay with sera of hepatitis E patients and reference groups: healthy donors, patients with hepatitis А, В, C, infectious mononucleosis and cytomegalovirus infection, HIV-infected patients. Conclusion. HEV genotype 1 ORF2 recombinant antigen had been developed, and its possible use in diagnostic tests had been experimentally shown.